The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A phase III randomised clinical trial

Hamid Reza Samimagham
Hormozgan University of Medical Sciences

Mehdi Hassani Azad
Hormozgan University of Medical Sciences

Maryam Haddad
Hormozgan University of Medical Sciences

Mohsen Arabi
Iran University of Medical Sciences: Tehran University of Medical Sciences

Dariush Hooshyar
Hormozgan University of Medical Sciences Faculty of Medicine

Mitra KazemiJahromi ( mitra.kazemijahromi@gmail.com )
Hormozgan University of Medical Sciences

Research

Keywords: Famotidine, COVID-19, Hospitalized

DOI: https://doi.org/10.21203/rs.3.rs-462937/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Introduction

As the first randomized clinical trial, this study evaluated the effect of Famotidine on the improvement of outcomes of hospitalized patients with COVID-19.

Method

This phase III randomized clinical trial was designed with two parallel arms, placebo-controlled, single-blind, and concealed allocation, and recruited 20 patients. Oral Famotidine 160 mg four times a day was given to patients until the discharge day or for a maximum of 14 days. Patients’ temperature, respiration rate, oxygen saturation, lung infiltration, lactate dehydrogenase (LDH) level and complete blood count (CBC) were measured at the baseline (before the intervention) and on day 14 after the intervention or on discharge day. Length of stay in the hospital and length of stay in the ICU were also measured as secondary outcomes of the study.

Results

The results showed a significant decrease in LDH (P = 0.01), mean WBC (P = 0.04) and length of stay (P = 0.04) of patients with COVID-19 in the group treated with Famotidine compared to the control group. There was also a significant increase in oxygen saturation (P = 0.01) in the group treated with Famotidine compared to the control group. Cough improvement was also higher in the oral Famotidine group compared to the control group (P = 0.02).

Conclusion

This was the first clinical trial on the effect of Famotidine on the improvement of hospitalized COVID-19 patients, which indicated that high-dose Famotidine improves patients’ clinical signs and reduces the severity of the disease and duration of hospitalization.

Introduction

Managing patients with COVID-19, which is caused by the SARS-CoV-2 virus, has become one of the challenges of healthcare systems today (1). Much research has recently focused on finding a vaccine and medication for these patients (2).

Famotidine is a low-cost, over-the-counter medication from histamine H2-receptor antagonists (H2RAs) family, which is widely used for its antacid properties (1). The results of computer simulation studies also identified Famotidine as a possible inhibitor of 3-chymotrypsin-like protease (3CL_pro) in the SARS-Cov-2 virus (2). Famotidine can also bind to histamine 2 receptors and modify subsequent signal pathways, including regulation of antibody production by B cells, release of cytokines by Th1, T cell differentiation
and division, mast cell degranulation, and dendritic cell responses (3). H2RAs have also manifested successful results against human immunodeficiency virus (HIV), papillomavirus, and hepatitis B (4).

There is no clinical trial to determine the effect of Famotidine on the improvement of patients with COVID-19 (5, 6).

Hence, considering the possible effects of Famotidine on the immune regulation in patients with COVID-19, the antiviral effects of H2RAs and the lack of relevant clinical trials, this study evaluated the effect of Famotidine on the recovery process, signs, and some laboratory results of hospitalized patients with COVID-19 as the first randomized clinical trial.

Methods

This phase III randomized clinical trial was designed with two parallel arms, placebo-controlled, single-blind, and concealed allocation, and recruited 20 patients. It was registered at the Iranian Registry of Clinical Trials (IRCT20200509047364N2) on 17 August 2020 (https://www.irct.ir/trial/49657), which is one of the primary partner registries for clinical trials of the World Health Organization. Data were collected from Shahid Mohammadi hospital in Bandar Abbas. Due to the lack of previous studies in this field, the sample size of 20 participant was considered for the study. (7)

Inclusion criteria

The main inclusion criteria before randomization were being infected with COVID-19 confirmed by a PCR test for SARS-Cov-2 and signing a written informed consent to participate in the study.

Exclusion Criteria

The main exclusion criteria before randomization were suffering from immunodeficiency, end-stage renal disease, moderate renal failure (creatinine clearance 30–50 ml/min), stage 4 severe chronic kidney disease, dialysis (creatinine clearance < 30 ml/min), history of liver disease, history of hepatitis C infection, history of alcoholism, Glucose-6-Phosphate Dehydrogenase Deficiency (G6PD), ALT/AST > 5 times normal limit, history or evidence of prolonged QT on ECG, history of psoriasis, history of porphyria, pregnancy, taking oral contraceptive pills (OCPs), taking Dasatinib, Neratinib, Ozanimod, Pazopanib, Rilpivirine, Siponimod or Tizanidine, and allergy to any medications used in this clinical trial.

Description of randomization

Before allocating each group to the eligible individuals in the study, informed consent for grouping the individuals was completed. Random sequences were prepared using online tools (https://www.sealedenvelope.com/) and block randomization method by a person who had no role in sampling or allocating individuals to random codes. Individual random allocation was done in blocks of 2 and 4 without stratification. Inclusion criteria were monitored by the recruiter and the codes in the random sequence were assigned to the patients by the treatment team who were blinded to whether each
code belonged to the intervention or placebo group. Then the patients’ codes for the interventions were matched with the generated random sequence information. (allocation concealment was performed by the treatment team without informing the recruiter and the person who prepared the random sequence).

**Description of blinding**

In this study, all participants were aware of participating in this study and entered the study with their consent. All participants were unaware of which group they were in and received Famotidine if they were assigned to the treatment group, and placebo if they were assigned to the control group. The first author, healthcare personnel, data collectors, and those who assessed the outcomes were aware of the patient grouping. Those who drafted the article were unaware of the grouping if they were not involved in the above processes.

**Intervention groups**

**Intervention group**

Group A received standard drug therapy according to the treatment protocols of the National Committee of COVID-19 plus oral Famotidine 160 mg (Chemi Darou Co.) four times a day until the discharge day or for a maximum of fourteen days. Also, the vital signs of the patients were frequently monitored at regular intervals.

Standard pharmacotherapy according to the National Committee of COVID-19 treatment protocols included: (i) Hydroxychloroquine/chloroquine phosphate: Hydroxychloroquine sulfate tablets 200 mg or chloroquine phosphate tablets 250 mg (equivalent to 150 mg base amount); 2 tablets every 12 hours on the first day and then 1 tablet every 12 hours for at least 7 days and up to 14 days. (ii) One of the following medications at the discretion of the treating physician: Kaletra tablets (lopinavir/ritonavir) 200/50 mg; 2 tablets every 12 hours after meals for at least 7 days and up to 14 days. (iii) Atazanavir/Ritonavir 300/100 tablet: 1 tablet a day with food; or Atazanavir 400 mg daily for a minimum of 7 days and a maximum of 14 days.

**Control group**

Group B received standard therapy according to the treatment protocols of the National Committee of COVID-19 plus placebo in form of oral tablets four times a day until the day of discharge or for a maximum of fourteen days.

**Primary outcomes**

Patients’ temperature, respiration rate, oxygen saturation, lung infiltration, lactate dehydrogenase and complete blood count were measured at the baseline (before the intervention) and on day 14 after the intervention or on the discharge day.

**Secondary outcomes**
Length of stay in the hospital and length of stay in the ICU were measured as secondary outcomes at the baseline (before the intervention) and on days 1 and 14 after the intervention or on the discharge day.

**Statistical analysis**

IBM-SPSS version 22 software will be used for data analysis, independent t-test and Mann-Whitney will be used to compare the means of quantitative data.

Chi-square and Fisher's test were used to compare qualitative variables.

**Results**

This study examined 20 patients with COVID-19. Their mean age was 46±13 years while 12 patients were male and 8 were female.

Patients were divided into two groups of ten:

**Treatment group:** They were treated with Famotidine in addition to standard COVID-19 treatment.

**Control group:** They were treated only with the COVID-19 standard treatment and pacebo.

In this study, the mean age of patients in the treatment and the control groups was 47±14 and 48±12 years, respectively. There was no statistically significant difference between the two groups (P=0.2).

Regarding gender frequency, 60% of patients were male and 40% were female in the treatment group, and 70% of patients were male and 30% were female in the control group. There was no statistically significant difference between the two groups (P=0.1).

**Comparison of laboratory findings and length of stay between the two groups**

The mean WBC on the discharge day was significantly lower in the treatment group (6550±2800) than that in the control group (10640±1600) (P=0.04).

LDH on the discharge day was significantly lower in the treatment group (584±158) than that in the control group (799±147) (P=0.01). Oxygen saturation on the discharge day was significantly higher in the treatment group (94±2%) than that in the control group (92±1%) (P=0.01) (Table 1).

Length of stay was significantly shorter in the treatment group (6±3 days) than that in the control group (9±4 days) (P=0.04). Cough improvement was significantly higher in the treatment group (7 patients (70%)) than that in the control group (4 patients (40%)) (P=0.02) (Table 1).

No death or ICU admission was reported in this study in either group.

There was no significant difference between the two groups in terms of comparing lung involvement on CT scan of patients on the discharge day. In both groups, 50% of patients had over half of their lungs
involved on the fifth day of admission (Table 1).

Table 1: Comparison of age, sex, clinical and laboratory variables between the treatment and control group

<table>
<thead>
<tr>
<th>P-value</th>
<th>Groups</th>
<th>Variables</th>
<th>Control</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Male</td>
<td>70%</td>
<td>60%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td></td>
<td>30%</td>
<td>40%</td>
<td></td>
</tr>
<tr>
<td>0.2</td>
<td></td>
<td>48±12</td>
<td>47±14</td>
<td></td>
</tr>
<tr>
<td>0.04</td>
<td></td>
<td>10640±1600</td>
<td>6550±2800</td>
<td></td>
</tr>
<tr>
<td>0.01</td>
<td></td>
<td>92±1</td>
<td>94±2</td>
<td></td>
</tr>
<tr>
<td>0.04</td>
<td></td>
<td>9±4</td>
<td>6±3</td>
<td></td>
</tr>
<tr>
<td>0.01</td>
<td></td>
<td>799±147</td>
<td>584±158</td>
<td></td>
</tr>
<tr>
<td>0.02</td>
<td></td>
<td>4 patients</td>
<td>7 patients</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>50%</td>
<td>50%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>More than 50% of lungs involved in CT scan on the fifth day of admission</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 patients</td>
<td>5 patients</td>
<td></td>
</tr>
</tbody>
</table>

Discussion

The results showed a significant decrease in LDH (P = 0.01) and length of stay (P = 0.04) in hospitalized patients with COVID-19 in the group treated with Famotidine compared to the control group. There was also a significant increase in oxygen saturation in the group treated with Famotidine compared to the control group. Cough improvement was also higher in the oral Famotidine group compared to the control group (P = 0.02).

The results of a computer simulation by Wu et al. showed the potential effect of Famotidine on 3CL\textsuperscript{pro} in SARS-COV-2 virus (8–10). The results of a study by Gupta et al. and other studies also showed that Famotidine could also act as a papain-like protease (PL\textsuperscript{pro}) inhibitor in the SARS-COV-2 virus, thereby inhibiting virus replication (11). The results of a computer study by Ortega et al. suggested administering other antiviral medications in combination with Famotidine (2, 3). They also investigated the pharmacokinetic effects of Famotidine on SARS-COV-2 virus and reported only intravenous administration of Famotidine as effective on viral proteases. (12). Loffredo et al. showed the ineffectiveness of Famotidine on the amount of 3CL\textsuperscript{pro} and PL\textsuperscript{pro} proteases in cultured cell lines (1). They also showed that, unlike computer studies, Famotidine had no antiviral effects on the replication of the
SARS-COV-2 virus (10). In this regard, Malone et al. also showed the effects of Famotidine only on the H2R receptor (8–10).

The effects of Famotidine on H2R can reduce the mediators of the immune system, and can lead to a decrease in proinflammatory factors as well as a decrease in airway inflammation through TH1 lymphocytes (11). Furthermore, another effect of Famotidine on the immune system is a reduction in the histamine release from mast cells, which are major producers of histamine in respiratory viral infections (8–10). Besides, Hogan et al. applied dual histamine blockade with cetirizine and Famotidine, and reported the promising effect of Famotidine on cytokine storm and a reduction in the signs and complaints of patients with COVID-19 (11).

To date, no clinical trial has evaluated the effect of Famotidine on the improvement of inpatients with COVID-19. A retrospective study by Freedberg et al. and a case series study by Janowitz et al. were the only studies that have reported the effect of Famotidine on the improvement of patients with COVID-19 (2, 3). The present study, as the first clinical trial to examine the effect of Famotidine on inpatients with COVID-19, evaluated the effect of high-dose oral Famotidine on the improvement of these patients. (2, 3)

Our results showed a significant increase in oxygen saturation in the oral Famotidine group compared to the control group (P = 0.01). Oxygen saturation in the case series reported by Malone et al. over a period of 2 hours showed changes from 93–98% on day 15 after starting the Famotidine treatment regimen (13). Similar to the present study, Janowitz et al. also reported an increase in oxygen saturation after Famotidine administration (13). However, we cannot compare the effectiveness of Famotidine or the recovery of patients based on an antiviral medication regimen because their study did not have a control group.

The present study also showed a significant reduction in the length of stay in patients with COVID-19 in the oral Famotidine group (P = 0.04). Cough improvement was also significantly higher in the oral Famotidine group compared to the control group in this study (P = 0.02). In the case reported in the study by Malone et al., a similar improvement in coughs was observed after administering Famotidine (2, 3). The improvement of cough in patients with COVID-19 has also been evaluated in the study by Janowitz et al. which was a case series study and reported a successful reduction in cough in patients after treatment with Famotidine (12).

LDH in patients with COVID-19 has been introduced as a marker for disease severity in various studies (14–18), and our results also showed a significant decrease in LDH levels in the Famotidine-treated group compared to the control group (P = 0.01). Our results also showed a significant decrease in WBC in the treatment group taking Famotidine compared to the control group taking placebo (P = 0.04).

The results of a retrospective study by Freedberg et al. on 1620 patients with COVID-19 showed a significant reduction in mortality and intubation risk in patients taking Famotidine (orally or intravenously, 40 or 20 mg daily); while patients taking proton pump inhibitors (PPIs) did not show a significant
reduction in the above variables (10). However, our results showed a successful reduction in patients’ respiratory complaints with Famotidine.

Our results regarding the gender of patients did not show a significant difference between the study groups. We also examined lung involvement on CT scan of patients and their age in both groups, which did not show a significant difference.

One of the limitations of our study was its small population, which presented itself in a decrease in statistical power in some tests which did not reach a significant level. Also, it was impossible to follow up patients after discharge.

Despite the small statistical population, our results showed improvement in patients taking oral Famotidine, which can be generalized to a larger population and suggests adding Famotidine to the treatment of patients with COVID-19. Furthermore, although our study does not determine the mechanism of action of Famotidine in these patients, according to the review of literature further studies are recommended on the effects of Famotidine on cytokine storm in patients with COVID-19.

**Conclusion**

This was the first clinical trial on the effect of Famotidine on the recovery of inpatients with COVID-19, which indicated that high-dose Famotidine improves patients’ clinical signs and reduces the severity of the disease and duration of hospitalization.

**Declarations**

**Ethics approval and consent to participate**

The protocol was approved by the ethics committee of Hormozgan University of Medical Sciences on August 2, 2020, with the code IR.HUMS.REC.1399.255. (https://ethics.research.ac.ir/ProposalView.php?id=143967)

Authors certify that this trial has received ethical approval from the appropriate ethical committee as described above. Informed consent will be obtained in Persian language, where the harms and benefits of the oral Famotidine and the placebo were described.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The authors have not yet decided on the sharing of information.

**Competing interests**
The authors declare that they have no competing interests.

**Funding**

This study is supported by the Deputy of Research and Technology of Hormozgan University of Medical Sciences. There was no influence regarding the study design, collection, analysis and interpretation by the funding body.

**Authors’ contributions**

M KJ. and HR S. designed the study. All the authors contributed in data collection and manuscript writing. M KJ supervised the study.

**Acknowledgements**

This work was a dissertation supported by Clinical Research Development Center of Shahid Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar-Abbas, Iran. We are sincerely thankful to Miss Tayyebeh Zaree in Clinical Research Development Center of Shahid Mohammadi Hospital.

**References**


Figures

CONSORT 2010 Flow Diagram

**Figure 1**

CONSORT 2010 Flow Diagram of the study participants

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- CONSORT2010Checklist.doc